Published in World J Gastroenterol on November 07, 2009
An intermediate dose of LCMV clone 13 causes prolonged morbidity that is maintained by CD4+ T cells. Virology (2012) 0.87
Adaptive immune response during hepatitis C virus infection. World J Gastroenterol (2014) 0.85
Kupffer cells potentiate liver sinusoidal endothelial cell injury in sepsis by ligating programmed cell death ligand-1. J Leukoc Biol (2013) 0.85
T cells increase before zoster and PD-1 expression increases at the time of zoster in immunosuppressed nonhuman primates latently infected with simian varicella virus. J Neurovirol (2014) 0.82
Lack of significant elevation of myeloid-derived suppressor cells in peripheral blood of chronically hepatitis C virus-infected individuals. J Virol (2014) 0.80
Inhibitors of the PD-1/PD-L1 Pathway Can Mobilize the Immune System: An Innovative Potential Therapy for Cancer and Chronic Infections. ACS Med Chem Lett (2015) 0.80
Ineffective CD8(+) T-cell immunity to adeno-associated virus can result in prolonged liver injury and fibrogenesis. Am J Pathol (2011) 0.78
Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis. World J Gastroenterol (2016) 0.78
Progress in the development of vaccines for hepatitis C virus infection. World J Gastroenterol (2015) 0.75
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 35.17
Restoring function in exhausted CD8 T cells during chronic viral infection. Nature (2005) 28.04
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature (2006) 20.00
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med (2000) 19.81
Hepatitis C virus infection. N Engl J Med (2001) 18.67
B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med (1999) 16.91
Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med (2006) 13.15
Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity (1999) 12.36
PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol (2001) 12.26
Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol (2008) 10.26
Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science (2001) 8.31
Fas ligand-induced apoptosis as a mechanism of immune privilege. Science (1995) 8.23
Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol (1989) 7.69
Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol (1996) 6.79
Replication of hepatitis C virus. J Gen Virol (2000) 6.08
Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J Virol (2006) 6.00
Homeostasis and anergy of CD4(+)CD25(+) suppressor T cells in vivo. Nat Immunol (2001) 5.95
Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature (2008) 5.94
Expression of programmed death 1 ligands by murine T cells and APC. J Immunol (2002) 5.78
Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature (2005) 5.50
PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J Virol (2006) 5.46
SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol (2004) 4.58
Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol (2002) 4.56
The PD-1-PD-L pathway in immunological tolerance. Trends Immunol (2006) 4.52
Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. J Virol (2001) 4.48
Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol (2007) 4.40
Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells. J Virol (2009) 3.90
Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction. J Virol (2007) 3.83
PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol (2002) 3.78
Hepatic T cells and liver tolerance. Nat Rev Immunol (2003) 3.51
PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and -gamma and mediates T cell apoptosis. J Hepatol (2006) 3.50
Population dynamics of immune responses to persistent viruses. Science (1996) 3.49
Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol (2003) 3.37
PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci U S A (2001) 3.32
An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection. Hepatology (2004) 3.18
PD-1 inhibits antiviral immunity at the effector phase in the liver. J Exp Med (2003) 3.05
Local control of the immune response in the liver. Immunol Rev (2000) 3.01
Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J Exp Med (2003) 3.00
Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C. J Infect Dis (2000) 2.98
Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization. Gastroenterology (2008) 2.95
PD-1 and its ligands in T-cell immunity. Curr Opin Immunol (2007) 2.86
Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection. J Exp Med (2008) 2.81
Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. Immunol Lett (2002) 2.80
Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection. Hepatology (2007) 2.78
The two-signal model of lymphocyte activation twenty-one years later. Immunol Today (1992) 2.62
T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection. J Virol (2005) 2.58
Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog (2009) 2.57
PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. J Clin Invest (2009) 2.26
Interaction between complement receptor gC1qR and hepatitis C virus core protein inhibits T-lymphocyte proliferation. J Clin Invest (2000) 2.25
Regulatory T cells suppress in vitro proliferation of virus-specific CD8+ T cells during persistent hepatitis C virus infection. J Virol (2005) 2.14
PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver. J Immunol (2007) 2.08
High level of PD-1 expression on hepatitis C virus (HCV)-specific CD8+ and CD4+ T cells during acute HCV infection, irrespective of clinical outcome. J Virol (2007) 2.01
The natural history of hepatitis C. Semin Liver Dis (2004) 1.95
Neighborhood politics: the immunoregulatory function of organ-resident liver endothelial cells. Trends Immunol (2001) 1.93
T-cell tolerance or function is determined by combinatorial costimulatory signals. EMBO J (2006) 1.92
Nonenveloped nucleocapsids of hepatitis C virus in the serum of infected patients. J Virol (2001) 1.84
Oscillating CD8(+) T cell effector functions after antigen recognition in the liver. Immunity (2005) 1.83
PD-1 blockade in rhesus macaques: impact on chronic infection and prophylactic vaccination. J Immunol (2009) 1.77
Structural and functional analysis of the costimulatory receptor programmed death-1. Immunity (2004) 1.70
Activation and inhibition of lymphocytes by costimulation. J Clin Invest (2002) 1.69
Bim-mediated deletion of antigen-specific CD8 T cells in patients unable to control HBV infection. J Clin Invest (2008) 1.62
Intrahepatic CD8+ T-cell failure during chronic hepatitis C virus infection. Hepatology (2005) 1.61
Treg suppressive activity involves estrogen-dependent expression of programmed death-1 (PD-1). Int Immunol (2007) 1.59
PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. Mol Immunol (2007) 1.58
Cutting edge: programmed death-1 expression is increased on immunocytes in chronic hepatitis C virus and predicts failure of response to antiviral therapy: race-dependent differences. J Immunol (2008) 1.57
Analysis of CD127 and KLRG1 expression on hepatitis C virus-specific CD8+ T cells reveals the existence of different memory T-cell subsets in the peripheral blood and liver. J Virol (2006) 1.52
Pathogenesis of hepatitis C-associated hepatocellular carcinoma. Gastroenterology (2004) 1.48
Regulated compartmentalization of programmed cell death-1 discriminates CD4+CD25+ resting regulatory T cells from activated T cells. J Immunol (2006) 1.40
Upregulation of PD-L1 on monocytes and dendritic cells by HIV-1 derived TLR ligands. AIDS (2008) 1.39
Antiviral therapy for chronic hepatitis C: past, present, and future. J Gastroenterol (2006) 1.28
PDL-1 upregulation on monocytes and T cells by HIV via type I interferon: restricted expression of type I interferon receptor by CCR5-expressing leukocytes. Clin Immunol (2008) 1.28
Blockade of PD-1/B7-H1 interaction restores effector CD8+ T cell responses in a hepatitis C virus core murine model. J Immunol (2008) 1.27
Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: effect of viremia levels and antiviral treatment. J Hepatol (2008) 1.23
T cell dysfunction by hepatitis C virus core protein involves PD-1/PDL-1 signaling. Viral Immunol (2007) 1.21
Early impairment of hepatitis C virus specific T cell proliferation during acute infection leads to failure of viral clearance. Gut (2006) 1.19
Reviving exhausted T lymphocytes during chronic virus infection by B7-H1 blockade. Trends Mol Med (2006) 1.12
Blocking of monocyte-associated B7-H1 (CD274) enhances HCV-specific T cell immunity in chronic hepatitis C infection. J Leukoc Biol (2007) 1.11
Turning on the off switch: regulation of anti-viral T cell responses in the liver by the PD-1/PD-L1 pathway. J Hepatol (2006) 1.06
Vaccination to treat persistent viral infection. Virology (2000) 1.05
Detection of hepatitis C virus core protein circulating within different virus particle populations. J Med Virol (1998) 1.00
Multiple combination therapies involving blockade of ICOS/B7RP-1 costimulation facilitate long-term islet allograft survival. Am J Transplant (2004) 1.00
Dynamic decrease in PD-1 expression correlates with HBV-specific memory CD8 T-cell development in acute self-limited hepatitis B patients. J Hepatol (2009) 0.98
Therapeutic vaccination in the immunotolerant phase of children with chronic hepatitis B infection. Pediatr Infect Dis J (2003) 0.98
HCV immunology--death and the maiden T cell. Cell Death Differ (2003) 0.97
Programmed death-1 expression is associated with the disease status in hepatitis B virus infection. World J Gastroenterol (2008) 0.92
Hepatitis C virus core protein induces an anergic state characterized by decreased interleukin-2 production and perturbation of mitogen-activated protein kinase responses. J Virol (2005) 0.85
Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus. Vaccine (2005) 0.82
Induction of potent and long-lasting CD4 and CD8 T-cell responses against hepatitis C virus by immunization with viral antigens plus poly(I:C) and anti-CD40. Antiviral Res (2007) 0.78
[Inhibition of the PD-1 pathway restores the effector function of HIV-specific T cells]. Med Sci (Paris) (2007) 0.77
[A new therapeutic strategy to control HIV? The PD1 molecule and its role in inhibiting cellular immune responses]. Gac Med Mex (2008) 0.76
[Expressions and significance of B7-H1 and programmed death-1 in lymphocytes from patients with chronic hepatitis B virus infection]. Zhonghua Gan Zang Bing Za Zhi (2007) 0.76
[PD-1 up-regulation influenced apoptosis of HBV-specific CD8 T cells in patients with acute resolved hepatitis B]. Zhonghua Yi Xue Za Zhi (2009) 0.76
Role of chemokines and their receptors in viral persistence and liver damage during chronic hepatitis C virus infection. World J Gastroenterol (2008) 1.26
The role of CCR5/CXCR3 expressing CD8+ cells in liver damage and viral control during persistent hepatitis C virus infection. J Hepatol (2007) 1.19
Bim-mediated apoptosis and PD-1/PD-L1 pathway impair reactivity of PD1(+)/CD127(-) HCV-specific CD8(+) cells targeting the virus in chronic hepatitis C virus infection. Cell Immunol (2011) 0.92
Cyclosporine A-induced apoptosis in renal tubular cells is related to oxidative damage and mitochondrial fission. Toxicol Lett (2013) 0.90
Oxidative stress by Helicobacter pylori causes apoptosis through mitochondrial pathway in gastric epithelial cells. Apoptosis (2008) 0.83
15-Deoxy-delta12,14-prostaglandin-J(2) up-regulates cyclooxygenase-2 but inhibits prostaglandin-E(2) production through a thiol antioxidant-sensitive mechanism. Pharmacol Res (2008) 0.83
All-trans retinoic acid and glycated albumin reciprocally influence their effects in human mesangial cells. Int J Vitam Nutr Res (2005) 0.76
Role of T cell death in maintaining immune tolerance during persistent viral hepatitis. World J Gastroenterol (2013) 0.76
Pros and Cons of Round Window Vibroplasty in Open Cavities: Audiological, Surgical, and Quality of Life Outcomes. Otol Neurotol (2015) 0.75
Usefulness of Electrical Auditory Brainstem Responses to Assess the Functionality of the Cochlear Nerve Using an Intracochlear Test Electrode. Otol Neurotol (2017) 0.75